All companies
Visit website
Aperio Beauty
OperatingAperio Genetics Inc.
Healthcare · Founded 2015
Personalized anti-aging skincare solutions
Post-money valuation ⓘ
$11.4M
As of Sep 2022 · from Aperio Beauty Common Stock 1 · pre-money + amount raised, not a traded price
Total raised
$52,553
Across 1 round since 2022
Latest share price
$1.25
Aperio Beauty Common Stock 1 offering price
Financials
FY2020–FY2021 · from SEC filings · hover any figure for its source$5K
−$260K
2020
$40K
−$452K
2021
RevenueNet income — beside revenue when positive, below the line when a loss
Metric
FY2020
FY2021
Income statement
Revenue
$4,622
$39,974
Cost of goods sold
$803
$19,253
Gross margin
83%
52%
Net income
-$260,404
-$451,719
Taxes paid
$0
$0
Balance sheet
Cash
$126,718
$130,972
Accounts receivable
$0
$10,403
Total assets
$486,827
$468,700
Short-term debt
$8,228
$14,811
Long-term debt
$922,312
$1,349,320
Total liabilities
$930,540
$1,364,131
Other
Headcount
—
2
Figures as reported by the issuer in the filing shown on hover. Each year’s pill shows the assurance level of its filed statements — audited, reviewed (CPA review, less than an audit), or unaudited; no pill means the filing didn’t state one. Headcount is the filing’s point-in-time count, not a year-end average. Manually corrected figures are marked “Corrected”.
Valuation over rounds
Post-money = pre-money + amount raised · caps marked$11.4M
post-money
Aperio Beauty Common Stock 1
A dashed amber step is a SAFE/note valuation cap — a conversion ceiling agreed for that instrument, not a priced valuation of the company. Steps are not comparable across bases.
Fundraising history
Raised $52.6K / $1.1MInvestors 27Post-money $11.4M
Reg CF annual-report compliance
Delinquent
Filed 0 of 4 annual reports (FY2022–FY2025)
Missing: 2022, 2023, 2024, 2025
27 investors
holder-count proxy
Reg CF issuers must file a Form C-AR each year until a Rule 202(b) termination trigger is met.
SEC filings
Source: ManualCIK 0001924358Share price $1.25
About this data. Figures are compiled from public sources — SEC EDGAR filings (Form C, C-AR, 1-A, 1-K) and funding-platform pages — and may be delayed, incomplete, or restated by the issuer. Financial statements are as reported by the issuer; each year is labeled with its assurance level (audited / reviewed / unaudited). A valuation cap is the conversion ceiling of a SAFE or convertible note, not an agreed company valuation; post-money figures are computed as pre-money plus amount raised and are not a traded price. Crowdonomics is not a broker-dealer, funding portal, or investment adviser; nothing here is investment advice or an offer to sell securities. Verify all figures against the linked EDGAR filings.